FI118538B - Menetelmä geeniterapiassa käytettävien adenoviraalisten eläinperäisten vektoreiden valmistamiseksi - Google Patents
Menetelmä geeniterapiassa käytettävien adenoviraalisten eläinperäisten vektoreiden valmistamiseksi Download PDFInfo
- Publication number
- FI118538B FI118538B FI955552A FI955552A FI118538B FI 118538 B FI118538 B FI 118538B FI 955552 A FI955552 A FI 955552A FI 955552 A FI955552 A FI 955552A FI 118538 B FI118538 B FI 118538B
- Authority
- FI
- Finland
- Prior art keywords
- adenovirus
- human
- therapeutic
- adenoviruses
- gene
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims description 32
- 238000001415 gene therapy Methods 0.000 title description 10
- 239000013598 vector Substances 0.000 title description 10
- 230000008569 process Effects 0.000 title description 3
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 73
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 241000598171 Human adenovirus sp. Species 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 241000701157 Canine mastadenovirus A Species 0.000 claims description 10
- 230000010076 replication Effects 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 230000001228 trophic effect Effects 0.000 claims description 4
- 102000007592 Apolipoproteins Human genes 0.000 claims description 3
- 108010071619 Apolipoproteins Proteins 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 3
- 102000008072 Lymphokines Human genes 0.000 claims description 3
- 108010074338 Lymphokines Proteins 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 239000003914 blood derivative Substances 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- -1 trophic factors Proteins 0.000 claims description 3
- 101150047856 Cav2 gene Proteins 0.000 claims description 2
- 206010053567 Coagulopathies Diseases 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 2
- 241000271566 Aves Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 21
- 238000002360 preparation method Methods 0.000 abstract description 9
- 238000001356 surgical procedure Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 65
- 241000700605 Viruses Species 0.000 description 28
- 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 25
- 102100038909 Caveolin-2 Human genes 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 15
- 239000012634 fragment Substances 0.000 description 13
- 210000005260 human cell Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 7
- 241000282465 Canis Species 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 108020005202 Viral DNA Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001135569 Human adenovirus 5 Species 0.000 description 4
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PXKSAXUKRMRORY-ZWKOTPCHSA-N 2-(3,4-dichlorophenyl)-n-[(1s,2r)-2-(2,5-dihydropyrrol-1-yl)cyclohexyl]-n-methylacetamide Chemical compound N1([C@@H]2CCCC[C@@H]2N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CC=CC1 PXKSAXUKRMRORY-ZWKOTPCHSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100035888 Caveolin-1 Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 101150005585 E3 gene Proteins 0.000 description 1
- 101150066038 E4 gene Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000715467 Homo sapiens Caveolin-1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000701168 Murine adenovirus 1 Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000188845 Porcine adenovirus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 241000701792 avian adenovirus Species 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9305954 | 1993-05-18 | ||
| FR9305954A FR2705361B1 (fr) | 1993-05-18 | 1993-05-18 | Vecteurs viraux et utilisation en thérapie génique. |
| FR9400531 | 1994-05-06 | ||
| PCT/FR1994/000531 WO1994026914A1 (fr) | 1993-05-18 | 1994-05-06 | Vecteurs adenoviraux d'origine animale et utilisation en therapie genique |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI955552A0 FI955552A0 (fi) | 1995-11-17 |
| FI955552L FI955552L (fi) | 1995-12-27 |
| FI118538B true FI118538B (fi) | 2007-12-14 |
Family
ID=9447235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI955552A FI118538B (fi) | 1993-05-18 | 1995-11-17 | Menetelmä geeniterapiassa käytettävien adenoviraalisten eläinperäisten vektoreiden valmistamiseksi |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6294377B1 (de) |
| EP (1) | EP0698108B2 (de) |
| JP (2) | JP3995259B2 (de) |
| KR (1) | KR100379569B1 (de) |
| CN (1) | CN1067722C (de) |
| AT (1) | ATE209686T1 (de) |
| AU (1) | AU696495B2 (de) |
| BR (1) | BR9406720A (de) |
| CA (1) | CA2163256C (de) |
| CZ (1) | CZ284903B6 (de) |
| DE (1) | DE69429260T3 (de) |
| DK (1) | DK0698108T4 (de) |
| ES (1) | ES2167365T5 (de) |
| FI (1) | FI118538B (de) |
| FR (1) | FR2705361B1 (de) |
| HU (1) | HU221340B1 (de) |
| IL (1) | IL109644A (de) |
| NO (1) | NO320818B1 (de) |
| NZ (1) | NZ266475A (de) |
| PL (1) | PL182814B1 (de) |
| PT (1) | PT698108E (de) |
| RU (1) | RU2233333C2 (de) |
| SK (1) | SK282354B6 (de) |
| UA (1) | UA66417C2 (de) |
| WO (1) | WO1994026914A1 (de) |
| ZA (1) | ZA943358B (de) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU663702B2 (en) | 1991-03-06 | 1995-10-19 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| IL113052A0 (en) | 1994-03-23 | 1995-06-29 | Rhone Poulenc Rorer Sa | Recombinant viruses, their preparation and their use in gene therapy |
| JP3816518B2 (ja) | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
| FR2722507B1 (fr) * | 1994-07-12 | 1996-08-14 | Rhone Poulenc Rorer Sa | Adenovirus comportant un gene codant pour une no synthase |
| FR2724320B1 (fr) * | 1994-09-13 | 1996-12-20 | Transgene Sa | Nouvel implant pour le traitement des maladies acquises |
| FR2725213B1 (fr) * | 1994-10-04 | 1996-11-08 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation en therapie genique |
| FR2726285B1 (fr) * | 1994-10-28 | 1996-11-29 | Centre Nat Rech Scient | Adenovirus depourvus de particules contaminantes viables, preparation et utilisation |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| CN100569297C (zh) | 1995-02-28 | 2009-12-16 | 加利福尼亚大学董事会 | 基因转移介导的血管形成疗法 |
| US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
| FR2731710B1 (fr) * | 1995-03-14 | 1997-04-30 | Rhone Poulenc Rorer Sa | Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique |
| FR2732357B1 (fr) | 1995-03-31 | 1997-04-30 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose |
| US5756283A (en) * | 1995-06-05 | 1998-05-26 | The Trustees Of The University Of Pennsylvania | Method for improved production of recombinant adeno-associated viruses for gene therapy |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| AU6261696A (en) * | 1995-06-05 | 1996-12-24 | Trustees Of The University Of Pennsylvania, The | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| US5698202A (en) * | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
| US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| ATE445705T1 (de) | 1995-06-15 | 2009-10-15 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante adenoviren zur gentherapie |
| US6265212B1 (en) | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| AUPN477695A0 (en) * | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| FR2740344B1 (fr) * | 1995-10-31 | 1997-11-21 | Rhone Poulenc Rorer Sa | Application de la proteine gax au traitement de cancers |
| WO1998000166A1 (en) * | 1996-07-03 | 1998-01-08 | Merial, Inc. | Recombinant canine adenovirus (cav) containing exogenous dna |
| AU4255397A (en) * | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
| US6638502B1 (en) | 1997-04-28 | 2003-10-28 | Gencell Sas | Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors |
| EP2386629A1 (de) | 1997-10-14 | 2011-11-16 | Darwin Molecular Corporation | Thymidinkinasemutanten und Fusionsproteine mit Thymidinkinase- und Guanylatkinaseaktivität |
| US6875606B1 (en) | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
| US6653088B1 (en) | 1997-10-24 | 2003-11-25 | Aventis Pharma S.A. | Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide |
| DK1049767T3 (da) | 1998-01-08 | 2005-09-19 | Aventis Pharma Inc | En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A) |
| US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US6225456B1 (en) | 1998-05-07 | 2001-05-01 | University Technololy Corporation | Ras suppressor SUR-5 |
| US6506889B1 (en) | 1998-05-19 | 2003-01-14 | University Technology Corporation | Ras suppressor SUR-8 and related compositions and methods |
| US6414129B1 (en) | 1998-08-11 | 2002-07-02 | Darwin Discovery Ltd. | Identification of the gene causing the mouse scurfy phenotype and its human ortholog |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| ES2350454T3 (es) | 1998-11-27 | 2011-01-24 | Ucb Pharma S.A. | Composiciones y métodos para incrementar la mineralización de la sustancia ósea. |
| US7063850B1 (en) | 1998-12-22 | 2006-06-20 | University Of Tennessee Research Foundation | Protective antigen of group A Streptococci |
| US6441156B1 (en) | 1998-12-30 | 2002-08-27 | The United States Of America As Represented By The Department Of Health And Human Services | Calcium channel compositions and methods of use thereof |
| FR2794771B1 (fr) | 1999-06-11 | 2001-08-10 | Aventis Pharma Sa | Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis) |
| FR2799472B1 (fr) | 1999-10-07 | 2004-07-16 | Aventis Pharma Sa | Preparation d'adenovirus recombinants et de banques adenovirales |
| WO2001048164A2 (en) | 1999-12-27 | 2001-07-05 | The Regents Of The University Of California | Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure |
| DE60142023D1 (de) | 2000-01-12 | 2010-06-17 | Univ Yale | Nogo rezeptor-vermittelte blockade des axonalen wachstums |
| AU2001245988A1 (en) | 2000-03-24 | 2001-10-08 | Biosphere Medical, Inc. | Microspheres for active embolization |
| GB0018307D0 (en) | 2000-07-26 | 2000-09-13 | Aventis Pharm Prod Inc | Polypeptides |
| US7060442B2 (en) | 2000-10-30 | 2006-06-13 | Regents Of The University Of Michigan | Modulators on Nod2 signaling |
| BR0116756A (pt) | 2000-12-28 | 2005-01-04 | Wyeth Corp | Proteìna protetora recombinante de streptococcus pneumoniae e uso da mesma |
| EP1967525B1 (de) | 2001-05-08 | 2012-11-14 | Darwin Molecular Corporation | Verfahren zur Regulierung der Immunfunktion in Primaten unter Verwendung des foxp3-Proteins |
| AUPR518501A0 (en) | 2001-05-22 | 2001-06-14 | Unisearch Limited | Yin yang-1 |
| AU2002325346A1 (en) | 2001-07-05 | 2003-01-21 | Aventis Pharma S.A. | Method of administration of a gene of interest to the heart and vasculature |
| US7582425B2 (en) | 2001-09-21 | 2009-09-01 | The Regents Of The University Of Michigan | Atlastin |
| US7108975B2 (en) | 2001-09-21 | 2006-09-19 | Regents Of The University Of Michigan | Atlastin |
| US20040023910A1 (en) * | 2001-09-28 | 2004-02-05 | Zhiming Zhang | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| AU2002365223A1 (en) | 2001-10-26 | 2003-09-02 | Id Biomedical Corporation Of Washington | Multivalent streptococcal vaccine compositions and methods for use |
| WO2003049763A1 (en) | 2001-12-12 | 2003-06-19 | Fh Faulding & Co Limited | Composition for the preservation of viruses |
| US20030158112A1 (en) | 2002-02-15 | 2003-08-21 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease |
| WO2003100008A2 (en) | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| FR2845395B1 (fr) * | 2002-10-08 | 2008-05-30 | Agronomique Inst Nat Rech | Vecteurs adenoviraux recombinants et leurs applications |
| US9532994B2 (en) | 2003-08-29 | 2017-01-03 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
| US7432057B2 (en) | 2004-01-30 | 2008-10-07 | Michigan State University | Genetic test for PSE-susceptible turkeys |
| RU2448157C2 (ru) | 2004-05-26 | 2012-04-20 | Псиоксус Терапьютикс Лимитед | Химерные аденовирусы для применения для лечения злокачественного новообразования |
| US7604798B2 (en) | 2004-07-15 | 2009-10-20 | Northwestern University | Methods and compositions for importing nucleic acids into cell nuclei |
| BRPI0513390A (pt) | 2004-07-16 | 2008-05-06 | Us Gov Health & Human Serv | vacinas contra aids contendo construções de ácido nucléico cmv/r |
| SI2002003T1 (sl) | 2005-05-27 | 2016-05-31 | Ospedale San Raffaele S.R.L. | Genski vektor, ki vsebuje mi-RNA |
| AU2007217366A1 (en) | 2006-02-27 | 2007-08-30 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| AU2007276793B2 (en) | 2006-07-28 | 2014-01-16 | Sanofi | Composition and method for treatment of tumors |
| PL2829551T3 (pl) | 2006-10-19 | 2018-04-30 | Csl Limited | Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13 |
| CA2666682C (en) | 2006-10-19 | 2014-07-08 | Merck & Co., Inc. | Anti-il-13r.alpha.1 antibodies and their uses thereof |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| CN101951915A (zh) | 2007-12-03 | 2011-01-19 | 加利福尼亚大学董事会 | 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇 |
| CN102203122A (zh) | 2008-11-05 | 2011-09-28 | 惠氏有限责任公司 | 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物 |
| EP2373338B1 (de) | 2008-12-03 | 2017-02-15 | The Johns Hopkins University | Annexin a2 als immunologisches zielmolekül |
| ES2629630T3 (es) * | 2008-12-04 | 2017-08-11 | Curna, Inc. | Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| WO2011116351A2 (en) | 2010-03-19 | 2011-09-22 | University Of South Alabama | Methods and compositions for the treatment of cancer |
| ES2664572T3 (es) * | 2010-05-26 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el homólogo atonal 1 (ATOH1) mediante inhibición del transcrito antisentido natural a ATOH1 |
| HUE054179T2 (hu) * | 2010-06-23 | 2021-08-30 | Curna Inc | Nátriumcsatornás, feszültségfüggõ, alfa alegységgel (SCNA) kapcsolatos betegségek kezelése a természetes antiszensz (SCNA)-transzkripció gátlásával |
| EP2608805B1 (de) | 2010-08-23 | 2017-07-05 | Wyeth LLC | Stabile formulierungen von neisseria-meningitidis-rlp2086-antigenen |
| MY166172A (en) | 2010-09-10 | 2018-06-07 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
| US9458456B2 (en) | 2011-04-01 | 2016-10-04 | University Of South Alabama | Methods and compositions for the diagnosis, classification, and treatment of cancer |
| WO2013103401A1 (en) | 2012-01-06 | 2013-07-11 | University Of South Alabama | Methods and compositions for the treatment of cancer |
| EP4043029A1 (de) | 2012-03-09 | 2022-08-17 | Pfizer Inc. | Neisseria meningitidis-zusammensetzungen und verfahren dafür |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| CN104395331B (zh) | 2012-05-07 | 2016-11-02 | 加利福尼亚大学董事会 | 诱导骨生成和hedgehog 信号传导且抑制脂肪形成的氧固醇类似物氧固醇化合物133 |
| WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
| EP2946016A4 (de) * | 2013-01-15 | 2016-11-23 | Univ California | Adenoviren und deren verwendung |
| CA2903716C (en) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Immunogenic fusion polypeptides |
| US10981961B2 (en) | 2013-03-11 | 2021-04-20 | University Of Florida Research Foundation, Incorporated | Delivery of card protein as therapy for occular inflammation |
| EP2991652A4 (de) | 2013-05-02 | 2016-12-07 | Univ California | Gegen knochen gerichtete knochenselektive osteogene oxysterol-wirkstoffe |
| EP3041502A2 (de) | 2013-09-08 | 2016-07-13 | Pfizer Inc. | Neisseria meningitidis-zusammensetzungen und verfahren dafür |
| EP3372236A1 (de) | 2013-10-25 | 2018-09-12 | PsiOxus Therapeutics Limited | Onkolytische adenoviren, die mit heterologen genen ausgestattet sind |
| WO2015127094A1 (en) | 2014-02-19 | 2015-08-27 | University Of Florida Research Foundation, Inc. | Delivery of nrf2 as therapy for protection against reactive oxygen species |
| KR102335810B1 (ko) * | 2014-06-17 | 2021-12-03 | 니뽄 신야쿠 가부시키가이샤 | 안티센스 핵산 |
| IL292999A (en) | 2014-11-14 | 2022-07-01 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| WO2016122791A1 (en) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Spinal subpial gene delivery system |
| CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
| CA2984038C (en) | 2015-04-30 | 2023-01-03 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a b7 protein |
| CN108289909A (zh) | 2015-10-19 | 2018-07-17 | 巴尔的摩马里兰大学 | 用于产生工程改造的人原代血液树突细胞系的方法 |
| US11155622B2 (en) | 2015-12-17 | 2021-10-26 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
| CN108884022B (zh) | 2016-03-28 | 2022-01-28 | 加利福尼亚大学董事会 | 用于治疗神经元的过度兴奋的方法和组合物 |
| US11560412B2 (en) | 2016-04-01 | 2023-01-24 | University Of Maryland, Baltimore | Compositions comprising GRIM-19 therapeutics and methods of use |
| JP7045362B2 (ja) | 2016-04-20 | 2022-03-31 | セントロ デ インベスティガシオンス エネルジェチカス メディオアンビエンタゥス イェ テクノロジカス オー．エイ． エム．ピー． | Ｐｋｌｒの遺伝子発現増強のための組成物および方法 |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| KR102427563B1 (ko) | 2016-08-29 | 2022-08-03 | 싸이오서스 테라퓨틱스 엘티디. | 이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스 |
| EA201990711A1 (ru) | 2016-09-20 | 2019-09-30 | Бёрингер Ингельхайм Ветмедика Гмбх | Новый ehv сайт инсерции orf70 |
| US10329586B2 (en) | 2016-09-20 | 2019-06-25 | Boehringer Ingelheim Vetmedica Gmbh | Canine adenovirus vectors |
| MY199909A (en) | 2016-09-20 | 2023-11-29 | Boehringer Ingelheim Vetmedica Gmbh | Promoters |
| EP3515480A1 (de) | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | Neuer schweinegrippenimpfstoff |
| PE20191107A1 (es) | 2017-01-31 | 2019-08-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos |
| AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
| EP3697452A4 (de) | 2017-10-16 | 2021-11-24 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. | Lentivirale vektoren zur verabreichung von pklr zur behandlung von pyruvatkinasemangel |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| US12036257B2 (en) | 2017-10-31 | 2024-07-16 | Kalivir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
| CN112567035A (zh) | 2018-07-02 | 2021-03-26 | 沃雅戈治疗公司 | 肌萎缩侧索硬化症及脊髓相关病症的治疗 |
| WO2020010035A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Cannula system |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| CA3185267A1 (en) | 2020-08-07 | 2022-02-10 | Spacecraft Seven, Llc | Plakophilin-2 (pkp2) gene therapy using aav vector |
| CA3215344A1 (en) | 2021-04-30 | 2022-11-03 | Kalivir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| CA3234811A1 (en) | 2021-10-20 | 2023-04-27 | Steven Goldman | Rejuvenation treatment of age-related white matter loss |
| CA3236365A1 (en) | 2021-11-02 | 2023-05-11 | University Of Rochester | Tcf7l2 mediated remyelination in the brain |
| WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
| WO2024163747A2 (en) | 2023-02-02 | 2024-08-08 | University Of Rochester | Competitive replacement of glial cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA858044B (en) * | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| IE903130A1 (en) * | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
| GB9001766D0 (en) * | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
| FR2681786A1 (fr) * | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
| FR2688514A1 (fr) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| AU670933B2 (en) * | 1992-03-27 | 1996-08-08 | Collimore Enterprises Pty Ltd | Formwork device |
-
1993
- 1993-05-18 FR FR9305954A patent/FR2705361B1/fr not_active Expired - Lifetime
-
1994
- 1994-05-06 CN CN94192150A patent/CN1067722C/zh not_active Expired - Lifetime
- 1994-05-06 DE DE69429260T patent/DE69429260T3/de not_active Expired - Lifetime
- 1994-05-06 PL PL94311660A patent/PL182814B1/pl unknown
- 1994-05-06 HU HU9503297A patent/HU221340B1/hu unknown
- 1994-05-06 US US08/553,317 patent/US6294377B1/en not_active Expired - Lifetime
- 1994-05-06 EP EP94916259A patent/EP0698108B2/de not_active Expired - Lifetime
- 1994-05-06 PT PT94916259T patent/PT698108E/pt unknown
- 1994-05-06 ES ES94916259T patent/ES2167365T5/es not_active Expired - Lifetime
- 1994-05-06 DK DK94916259T patent/DK0698108T4/da active
- 1994-05-06 CZ CZ953028A patent/CZ284903B6/cs not_active IP Right Cessation
- 1994-05-06 WO PCT/FR1994/000531 patent/WO1994026914A1/fr active IP Right Grant
- 1994-05-06 AU AU67878/94A patent/AU696495B2/en not_active Expired
- 1994-05-06 RU RU95122419/13A patent/RU2233333C2/ru active
- 1994-05-06 BR BR9406720A patent/BR9406720A/pt not_active Application Discontinuation
- 1994-05-06 NZ NZ266475A patent/NZ266475A/xx not_active IP Right Cessation
- 1994-05-06 AT AT94916259T patent/ATE209686T1/de active
- 1994-05-06 KR KR1019950705128A patent/KR100379569B1/ko not_active IP Right Cessation
- 1994-05-06 CA CA002163256A patent/CA2163256C/fr not_active Expired - Lifetime
- 1994-05-06 SK SK1447-95A patent/SK282354B6/sk not_active IP Right Cessation
- 1994-05-06 UA UA95114778A patent/UA66417C2/xx unknown
- 1994-05-06 JP JP52504994A patent/JP3995259B2/ja not_active Expired - Lifetime
- 1994-05-12 IL IL10964494A patent/IL109644A/xx not_active IP Right Cessation
- 1994-05-16 ZA ZA943358A patent/ZA943358B/xx unknown
-
1995
- 1995-11-07 NO NO19954466A patent/NO320818B1/no not_active IP Right Cessation
- 1995-11-17 FI FI955552A patent/FI118538B/fi not_active IP Right Cessation
-
2004
- 2004-02-05 JP JP2004029636A patent/JP2004180689A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI118538B (fi) | Menetelmä geeniterapiassa käytettävien adenoviraalisten eläinperäisten vektoreiden valmistamiseksi | |
| KR100356615B1 (ko) | 결함아데노바이러스벡터및유전자치료에서그의사용 | |
| EP0704534A2 (de) | Rekombinanter viraler DNS Vektor zur Transfektion tierischer Zellen | |
| JP4376454B2 (ja) | アデノウイルスベクター及び相同組換えイベントの低減方法 | |
| KR100575521B1 (ko) | 재조합 아데노 바이러스 게놈의 제조 방법 | |
| JPH10507922A (ja) | 生存汚染粒子を持たないアデノウィルス、その製造および使用 | |
| JP4386971B2 (ja) | スプライシング配列を含んでなる組換えアデノウイルスベクター | |
| JPH10506018A (ja) | 不活化ＩＶａ２遺伝子を有する欠陥組換えアデノウィルス | |
| ES2239841T3 (es) | Vectores adenovirales quimericos. | |
| Wu et al. | Effective modifications for improved homologous recombination and high-efficiency generation of recombinant adenovirus-based vectors | |
| US7264818B2 (en) | BAV packaging regions and E1 transcriptional control regions | |
| WO2004078987A1 (fr) | Produit de recombinaison construit a partir d'un vecteur viral et d'un gene humain suppresseur de tumeur et utilisation dudit produit de recombinaison |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 118538 Country of ref document: FI |
|
| PC | Transfer of assignment of patent |
Owner name: AVENTIS PHARMA S.A. Free format text: AVENTIS PHARMA S.A. |
|
| MA | Patent expired |